Cibus Q2 net loss $22.1M, cash $20.4M, EU gene-editing rule favorable, Interoc expands to 5 Rice traits

Cibus, Inc.

Net loss $22.1M vs $26.6M YoY; EPS -$0.29 vs -$0.61.
Cash $20.4M; expects to fund into early Q1 2027; quarterly net cash usage down 19% QoQ, 31% YoY.
EU approved gene-edited crops as conventional (June 2026); supports Rice and other programs.
Interoc amended LOI to expand from 2 to 5 Rice traits; potential 2028 launch.
Craig Wichner appointed CEO effective June 8, 2026; Peter Beetham remains President/COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.